The largest holder of Boston Scientific stock is Vanguard Capital Management LLC, with 97.1 million shares (6.56% of the company), worth about $4.69 billion as of September 25, 2026. The 10 largest holders together own 34.0%.
In Q2 2026, 1,591 institutional holdings reports listed 1.43 billion shares worth $62.60 billion, up 6.7% in shares from Q1 2026.
Insiders reported 88 transactions in the last two years: 25 sales worth $110.51 million and no purchases. The newest one on file is from May 7, 2026 (Mega Jessica L M.D., Director).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 7, 2026.

2026Q2
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Vanguard Capital Management LLC | 97.1 million | 6.56% | $4.7B |
| BlackRock Advisors LLC | 92.9 million | 6.28% | $4.5B |
| State Street Corporation | 70.1 million | 4.74% | $3.4B |
| PRIMECAP Management Co. | 50.5 million | 3.42% | $2.4B |
| Fidelity Management & Research Co. LLC | 45.7 million | 3.09% | $2.2B |
| Geode Capital Management LLC | 33.4 million | 2.26% | $1.6B |
| BlackRock Life Ltd. | 32.3 million | 2.19% | $1.6B |
| Vanguard Portfolio Management LLC | 29.8 million | 2.01% | $1.4B |
| D.E. Shaw & Co., Inc. | 25.5 million | 1.72% | $1.2B |
| MFS Investment Management Canada Ltd. | 24.9 million | 1.68% | $1.2B |
As of September 25, 2026.
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 1,591 | 1.43 billion | $62.6B |
| Q1 2026 | 1,787 | 1.34 billion | $84.4B |
| Q4 2025 | 1,884 | 1.37 billion | $131.0B |
| Q3 2025 | 1,820 | 1.38 billion | $134.0B |
| Q2 2025 | 1,801 | 1.37 billion | $147.0B |
| Q1 2025 | 1,750 | 1.35 billion | $136.0B |
| Q4 2024 | 1,617 | 1.34 billion | $120.0B |
| Q3 2024 | 1,498 | 1.35 billion | $113.0B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Mega Jessica L M.D. | May 7, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Morano Susan E. | May 7, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Weber Christophe Pierre | May 7, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Wichmann David S | May 7, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Habiger David C | May 7, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Zane Ellen M | May 7, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Ludwig Edward J. | May 7, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| O'Connor Padraig Andrew | May 1, 2026 | Officer | -- | – |
| Butcher Arthur C | May 1, 2026 | Officer | -- | – |
| Morano Susan E. | Mar 2, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Weber Christophe Pierre | Mar 2, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Woodworth Emily | Feb 27, 2026 | Officer | -- | – |
Newest 12 of 88 insider transactions in the last two years.
Vanguard Capital Management LLC, with 6.56% of the company (as of September 25, 2026). Next: BlackRock Advisors LLC (6.28%) and State Street Corporation (4.74%).
1,591 institutional holdings reports listed Boston Scientific shares in Q2 2026, 1.43 billion shares in all worth $62.60 billion.
In the last two years insiders reported 25 sales and no purchases (88 transactions in all); the newest on file is from May 7, 2026.